1997 - ASM Award for Research in Clinical Microbiology, American Society for Microbiology
Michael A. Pfaller mostly deals with Microbiology, Fluconazole, Candida albicans, Mycosis and Corpus albicans. Fungi imperfecti, Caspofungin, Candida glabrata, Echinocandin and Drug resistance are among the areas of Microbiology where Michael A. Pfaller concentrates his study. Michael A. Pfaller has researched Candida glabrata in several fields, including Candida parapsilosis and Candida tropicalis.
His Fluconazole study combines topics from a wide range of disciplines, such as Amphotericin B, Voriconazole, Broth microdilution and Itraconazole. His work carried out in the field of Candida albicans brings together such families of science as Epidemiology and Intensive care medicine. His biological study spans a wide range of topics, including Attributable mortality, Internal medicine, Risk factor and Pediatrics.
His main research concerns Microbiology, Fluconazole, Candida albicans, Broth microdilution and Antimicrobial. His research in Antibacterial agent, Candida glabrata, Fungi imperfecti, Caspofungin and Amphotericin B are components of Microbiology. His Fluconazole research is multidisciplinary, relying on both Minimum inhibitory concentration, Itraconazole, Voriconazole and Mycosis.
In Mycosis, Michael A. Pfaller works on issues like Internal medicine, which are connected to Immunology. Michael A. Pfaller does research in Candida albicans, focusing on Corpus albicans specifically. His Broth microdilution research includes elements of Streptococcus pneumoniae, Etest and Staphylococcus aureus.
Michael A. Pfaller mainly focuses on Microbiology, Antimicrobial, Staphylococcus aureus, Broth microdilution and Linezolid. His study on Microbiology is mostly dedicated to connecting different topics, such as Enterococcus faecalis. The study incorporates disciplines such as Pseudomonas aeruginosa, Enterobacteriaceae, Bacteremia and Cephalosporin in addition to Antimicrobial.
His studies deal with areas such as Klebsiella pneumoniae, Antibiotic resistance and Bacterial pneumonia as well as Staphylococcus aureus. Michael A. Pfaller combines subjects such as Tigecycline and Meropenem with his study of Broth microdilution. His Linezolid research also works with subjects such as
His primary areas of study are Microbiology, Broth microdilution, Echinocandin, Candida glabrata and Staphylococcus aureus. The Microbiology study combines topics in areas such as Pseudomonas aeruginosa and Enterococcus faecalis. His Echinocandin research integrates issues from Voriconazole and Echinocandins.
His study looks at the intersection of Candida glabrata and topics like Anidulafungin with Candida tropicalis, Candida parapsilosis and Candida dubliniensis. Michael A. Pfaller has included themes like Haemophilus influenzae, Antibiotic resistance and Streptococcus pneumoniae in his Staphylococcus aureus study. The various areas that he examines in his Fluconazole study include Cryptococcus neoformans and Candida albicans.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Manual of clinical microbiology
Patrick R. Murray;Ellen Jo Baron;James H. Jorgensen;Marie L. Landry.
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
M. A. Pfaller;D. J. Diekema.
Clinical Microbiology Reviews (2007)
Nosocomial Bloodstream Infections in United States Hospitals: A Three-Year Analysis
Michael B. Edmond;Sarah E. Wallace;Donna K. McClish;Michael A. Pfaller.
Clinical Infectious Diseases (1999)
Attributable Mortality of Nosocomial Candidemia, Revisited
Olafur Gudlaugsson;Olafur Gudlaugsson;Shane Gillespie;Kathleen Lee;Jeff Vande Berg.
Clinical Infectious Diseases (2003)
Hospital-Acquired Candidemia: The Attributable Mortality and Excess Length of Stay
Sergio B. Wey;Motomi Mori;Michael A. Pfaller;Robert F. Woolson.
JAMA Internal Medicine (1988)
Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections
John H. Rex;Michael A. Pfaller;John N. Galgiani;Marilyn S. Bartlett.
Clinical Infectious Diseases (1997)
RESISTANCE OF CANDIDA SPECIES TO FLUCONAZOLE
J H Rex;M G Rinaldi;M A Pfaller.
Antimicrobial Agents and Chemotherapy (1995)
Epidemiology and Outcomes of Candidemia in 2019 Patients: Data from the Prospective Antifungal Therapy Alliance Registry
David L. Horn;Dionissios Neofytos;Dionissios Neofytos;Elias J. Anaissie;Jay A. Fishman.
Clinical Infectious Diseases (2009)
Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment.
Michael A. Pfaller.
The American Journal of Medicine (2012)
Epidemiology of Invasive Mycoses in North America
Michael A. Pfaller;Daniel J. Diekema.
Critical Reviews in Microbiology (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: